Effectiveness of Rotavirus Vaccination: A Systematic Review of the First Decade of Global Postlicensure Data, 2006-2016

Clin Infect Dis. 2017 Sep 1;65(5):840-850. doi: 10.1093/cid/cix369.


Two rotavirus vaccines, Rotarix (RV1) and RotaTeq (RV5), were licensed for global use in 2006. A systematic review of 48 peer- reviewed articles with postlicensure data from 24 countries showed a median RV1 vaccine effectiveness (VE) of 84%, 75%, and 57% in countries with low, medium, and high child mortality, respectively, and RV5 VE of 90% and 45% in countries with low and high child mortality, respectively. A partial vaccine series provided considerable protection, but not to the same level as a full series. VE tended to decline in the second year of life, particularly in medium- and high-mortality settings, and tended to be greater against more severe rotavirus disease. Postlicensure data from countries across geographic regions and with different child mortality levels demonstrate that under routine use, both RV1 and RV5 are effective against rotavirus disease, supporting the World Health Organization recommendation that all countries introduce rotavirus vaccine into their national immunization program.

Keywords: rotavirus vaccine; vaccine effectiveness.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Child
  • Child, Preschool
  • Developing Countries
  • Humans
  • Infant
  • Infant, Newborn
  • Rotavirus Infections* / epidemiology
  • Rotavirus Infections* / prevention & control
  • Rotavirus Vaccines* / administration & dosage
  • Rotavirus Vaccines* / therapeutic use
  • Vaccination / statistics & numerical data*
  • Vaccines, Attenuated / administration & dosage
  • Vaccines, Attenuated / therapeutic use


  • RIX4414 vaccine
  • RotaTeq
  • Rotavirus Vaccines
  • Vaccines, Attenuated